When does DSM-Firmenich report earnings and why does it matter?

DSM-Firmenich reports 2025 results on 12 Feb 2026. The report matters because management will detail the ANH divestment, the timing of the **€0.50 billion** buyback, and updated cash and dividend guidance.

What valuation metrics matter for DSFIR.AS stock?

Key metrics are EPS **€2.72**, PE **25.92**, price/book **0.87**, and dividend per share **€2.50**. Watch free cash flow and margin trends after the ANH separation for re-rating potential.

How does the ANH sale affect financials and shareholder returns?

The ANH sale should free **≈€1.20 billion** in cash post-close and enable the planned **€0.50 billion** buyback. Expect a one-off **€1.90 billion** non-cash impairment and **€0.20 billion** of separation costs in 2026.

What is Meyka AI’s near-term forecast for DSFIR.AS?

Meyka AI's forecast model projects a monthly level at **€72.06**, implying **7.85%** upside from **€66.82**. Forecasts are model-based projections and not guarantees.

EU Stocks

DSFIR.AS DSM-Firmenich EURONEXT pre-market 11 Feb 2026: earnings focus on ANH sale

ByDanny Kontos February 11, 2026February 11, 2026

We start pre-market on 11 Feb 2026 with DSM-Firmenich (DSFIR.AS) trading at €66.82 and an earnings release due on 12 Feb 2026. DSFIR.AS stock will be watched closely after the announced sale of the Animal Nutrition & Health unit for €2.20 billion and a new €0.50 billion buyback plan. Investors must weigh the near-term non-cash impairment and cash proceeds against a stable dividend policy of €2.50 per share. This earnings spotlight explains the likely read-throughs for revenue, margins, and shareholder returns ahead of tomorrow’s report.